BioSpace News Archive

Scientists haven’t quite decoded how animals smell, but researchers at Cold Spring Harbor Laboratory found that it’s different from previously thought.

Accelerating new treatment options for Canadians

Gilead Sciences, Inc. (NASDAQ: GILD) today presented the first clinical data in people living with HIV on GS-6207, an investigational, novel, selective, first-in-class inhibitor of HIV capsid function.

Rheonix Inc. and Mérieux NutriSciences announce the successful conclusion of early-access customer evaluations of the Listeria PatternAlert™ assay, a breakthrough method for rapidly identifying molecular patterns from Listeria strains

As part of their commitment to nursing education and the future of healthcare, Galen College of Nursing announces the expansion of its Hazard campus at the ARH System Center in Hazard, Kentucky.

Seeking to transform the education and well-being of current and future doctors, South Dakota businessman and philanthropist T. Denny Sanford has created a new institute at the University of California San Diego.

Applied BioMath (www.appliedbiomath.com), the industry leader in applying systems and mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development, is proud to welcome Alison Betts, as Senior Director of Scientific Collaborations and Fellow of Modeling & Simulation

The Football Writers Association of America and the National Foundation for Infectious Diseases will again partner to present the 2019 Outland Trophy as part of a continued public awareness campaign on the importance of influenza prevention during the 2019-2020 flu season.

Gilead Sciences, Inc. (NASDAQ: GILD) today presented findings from two Phase 3 trials – a trial demonstrating the effectiveness of switching to Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced positive Week 96 results from the phase III BRIGHTE study of investigational fostemsavir in heavily treatment-experienced adults with HIV-1 infection.